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96 ReviewAdjuvant analgesics in neuropathic pain
Vincent K.F. Kong and Michael G. IrwinConventional analgesics have limited efficacy in the
management of neuropathic pain. An adjuvant analgesic is a
drug that has a primary nonpain indication but whichmay be
analgesic in certain circumstances, and many of these have
established a role in the pharmacological treatment of
neuropathic pain. The number needed to treat is an indirect
statistical measure that can be used to compare relative
efficacy of different adjuvant analgesics and, from this, there
is currently insufficient evidence to suggest that any one
adjuvant analgesic has absolute advantages over another.
Analgesic efficacy, tolerability, safety/toxicity, drug
interactions, ease of use, and cost-effectiveness are
essential factors that guide the selection of an adjuvant
analgesic. Cost-effectiveness data are absent for the
vast majority of these drugs. Pharmacological treatments
should be used as part of a multimodal therapeuticight © European Society of Anaesthesiology. Una
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Neuropathic pain is the result of an injury or malfunction
in the peripheral or central nervous system. It may affect
up to 8% of adults in the UK and is one of the most
difficult types of chronic pain to treat as well as having a
devastating impact on psychological health, social func-
tioning, and other aspects of health-related quality of life
(QoL) [1]. Nearly 50% of patients with neuropathic pain
have inadequate pain relief, and conventional analgesics
are generally not effective [2]. Adjuvant analgesics are
drugs (with different mechanisms of action, Table 1) that
may primarily have nonpain indications but which may
be analgesic in certain circumstances. Although adjuvant
analgesics have long been the mainstay of pharmacologi-
cal treatment of neuropathic pain, only a few are specifi-
cally licensed for this indication (Table 2). The clinical
decision to prescribe drugs for ‘off-label’ indications
should be ideally based on professional judgement in
terms of safety quality, and efficacy. Currently available
pharmacologic agents with proven efficacy are: anticon-
vulsants, antidepressants, topical preparations, and some
novel agents. Those that have been approved for neuro-
pathic pain management include carbamazepine, pheny-
toin, gabapentin, pregabalin, duloxetine, lidocaine plas-
ter, capsaicin and sativex (GW Pharmaceuticals,
Salisbury, Wiltshire, UK). These will be discussed in
this review after a brief introduction of number needed
to treat (NNT) and number needed to harm (NNH).
Numbers needed to treat and numbers
needed to harm
The NNT is a clinically useful measure for assessing,
comparing, pooling and reporting relative effectivenessof interventions in the absence of head-to-head or direct
comparisons. It is the number of people who must be
treated for one person to benefit over a defined period of
time and is calculated as the reciprocal value of an
absolute risk reduction, that is, the difference between
the proportion of events in the control group (Pc) and the
proportion of events in the intervention group (Pi)
[Eq. (1)] [3]. NNTs are treatment specific, outcome
specific, and are relative to the comparator within a
defined period of time. NNT also depends on the base-
line risk of events. Practically speaking, a NNT of two or
three would normally indicate an effective therapy. The
NNT can be applied to an adverse event, when it
becomes the NNH. Unlike the NNT, the NNH should
preferably be as large as possible, indicating a low prob-
ability of such an event. The discrepancy between
NNH and NNT reflects the therapeutic index of a
treatment.
Number needed to treat ¼ 1=ðPc  PiÞ (1)
Pooled NNT values from multiple trials are commonly
presented in meta-analyses to summarize treatment
effects in a clinically relevant way. Making clinical de-
cisions based on pooled NNT values may be misleading
due to variation in the baseline risks between the trials
such as differences in patient characteristics, clinical
settings, treatment durations, outcome measures, and
disease incidences [4]. Moreover, pooled NNT values
are not adjusted for study quality or sample size. As a
single measure of health benefit, NNT conveys some but
not all the necessary information for making clinical
decisions.uthorized reproduction of this article is prohibited.
DOI:10.1097/EJA.0b013e328318c706
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Table 1 Mechanisms of action of adjuvant analgesics for neuropathic pain
Drug classes Adjuvant analgesics Proposed mechanism(s) of action
Anticonvulsants Carbamazepine Sodium-channel blocker; serotonergic receptor agonist; serotonin reuptake inhibitor
Phenytoin Sodium-channel blocker
Gabapentin/pregabalin Modulation of cellular calcium influx into nociceptive neurons: binding to the a2d subunit of VGCCs;
reduction in neurotransmitter release; decrease in neuronal hyperexcitability
Antidepressants TCAs Serotonin, noradrenaline, and dopamine reuptake inhibitor; sodium, potassium, and calcium-channel blocker;
a-adrenergic, cholinergic, and histaminic blockade; effects on GABA and adenosine; NMDA-receptor
antagonist; modulation of descending inhibitory pathways
Venlafaxine Dual serotonin and noradrenaline reuptake inhibitor (weak noradrenaline reuptake inhibitor at low dose);
sodium-channel blocker
Duloxetine Potent balanced serotonin and noradrenaline reuptake inhibitor
Topical agents Lidocaine patch Sodium-channel blocker; physical barrier against mechanical stimulation
Capsaicin cream Activation of vanilloid neuronal membrane receptors on subpopulations of sensory nociceptive C or Ad fibres;
prolonged desensitization of capsaicin-sensitive nociceptors; depletion of substance P
Others Cannabinoids Peripheral and central cannabinoid receptors (CB1 and CB2) agonists
Ziconotide Neuron-specific N-type voltage-sensitive calcium-channel blocker; inhibition of neurotransmitter release
GABA, g-aminobutyric acid; NMDA, N-methyl-D-aspartate; TCAs, tricyclic antidepressants; VGCCs, voltage-gated Ca2þ channels.Anticonvulsants
The basis for the use of anticonvulsants for the treatment
of neuropathic pain stems from some similarities in the
pathophysiology with epilepsy. They have been used for
this purpose for over 40 years. In the UK, carbamazepine
and phenytoin are licensed for the treatment of neuro-
pathic pain associated with trigeminal neuralgia. Carba-
mazepine is a traditional treatment for trigeminal neur-
algia. It blocks voltage-dependent sodium channels,
reduces ectopic nerve discharges and stabilizes neural
membranes [5]. Carbamazepine had a NNT of 1.9 [95%
confidence interval (CI) 1.4–2.8] for any pain relief in
trigeminal neuralgia (two studies in the 1960s, 47 partici-
pants receiving carbamazepine), a NNT of 2.5 (95% CI
1.8–3.8) for at least moderate pain relief in any neuro-
pathic pain (four studies, 91 participants), and a NNH of
3.7 (95% CI 2.4–7.8) for minor adverse effects [6]. Phe-
nytoin is one of the oldest adjuvant analgesics. It has an
inhibitory effect on presynaptic glutamate release in
addition to sodium-channel blockade [7]. The NNT of
phenytoin for effectiveness in diabetic neuropathy (one
study, 38 participants receiving phenytoin) was 2.1 (95%
CI 1.5–3.6) [8]. Use of these older anticonvulsants is
often restricted by the need for pharmacokinetic monitor-
ing, unfavourable tolerability, side-effect profiles, and
significant drug interactions.right © European Society of Anaesthesiology. Un
Table 2 Adjuvant analgesics licensed for neuropathic pain
Drug classes Generic name
Approved neuropathic p
In the UK
Anticonvulsants Carbamazepine Trigeminal neuralgia
Phenytoin Trigeminal neuralgia
Gabapentin Neuropathic pain
Pregabalin Peripheral and central ne
Antidepressants Duloxetine Painful diabetic peripher
Topical agents Lidocaine 5% patch PHN
Capsaicin 0.075% cream PHN and painful diabetic
PHN, postherpetic neuralgia.Gabapentin, a structural analogue of the neurotransmitter
g-aminobutyric acid (GABA), was initially introduced as
an anticonvulsant but subsequently shown to have
analgesic properties. After binding to the a2d subunit
of voltage-dependent Ca2þ channels (VGCCs), there is a
reduction in neurotransmitter release and hence a
decrease in neuronal hyperexcitability [9]. It was shown
to be effective for the treatment of a variety of neuro-
pathic pain conditions in doses up to 3600mg daily [10]
(Table 3). There were significantly greater improve-
ments in QoL parameters in gabapentin-treated patients
compared with patients who received placebo. Gabapen-
tin has a favourable safety and tolerability profile. Com-
mon side effects were dizziness, somnolence, headache,
diarrhoea, confusion and nausea, but, interestingly, there
was no significant difference between gabapentin and
placebo for withdrawal due to adverse effects. Gabapen-
tin is an attractive agent for patients receiving multiple
medications due to the lack of major drug interactions
and it is now available in generic formulations.
Pregabalin, an a2d ligand with anticonvulsant, analgesic
and anxiolytic properties, was designed as a more potent
successor to gabapentin. It probably has a similar mech-
anism of action, but, when compared with gabapentin,
pregabalin has the advantages of six times higher affinityauthorized reproduction of this article is prohibited.
ain conditions
In the USA
PHN
uropathic pain PHN and painful diabetic peripheral neuropathy
al neuropathy
peripheral neuropathy
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Table 3 Gabapentin for chronic neuropathic pain
Neuropathic pain conditions
NNT for moderate or better improvement
(compared with placebo) Pooled sample size
Diabetic neuropathy 2.9 (95% CI 2.2–4.3) RR 2.2 (95% CI 1.7–3) 281 patients (four studies)
PHN 3.9 (95% CI 3–5.7) RR 2.5 (95% CI 1.8–3.3) 428 patients (two studies)
All neuropathic pain 4.3 (95% CI 3.5–5.7) RR 2.2 (95% CI 1.8–2.7) 941 patients (six studies)
Adverse effects NNH (compared with placebo)
Minor harm (tolerable adverse effects) 3.7 (95% CI 2.4–5.4) 269 patients (two studies)
Major harm (any effect leading to withdrawal from the studies)
No statistically significant difference between gabapentin and placebo groups
Data from 1075 patients (five studies)
CI, confidence interval; NNH, number needed to harm; NNT, number needed to treat; PHN, postherpetic neuralgia; RR, relative risk. Adapted from [7].for the presynaptic calcium channel, more rapid onset of
action, high oral bioavailability and linear pharmacoki-
netics [11]. Pregabalin was licensed in the UK for periph-
eral neuropathic pain syndromes in 2004 and central
neuropathic pain in 2006. More recently, it has acquired
an indication for the treatment of generalized anxiety
disorder.
Pregabalin has been assessed in nearly 2000 patients from
eight clinical trials for the treatment of neuropathic pain
in patients with postherpetic neuralgia (PHN), painful
diabetic peripheral neuropathy (DPN) and spinal cord
injury [12]. It was associated with rapid and sustainable
reduction in neuropathic pain and its associated sleep
interference at dosage ranging from 150 to 600mgday1.
Common adverse effects were dizziness, somnolence,
peripheral oedema, weight gain, dry mouth, asthenia
and blurred vision. For PHN and DPN, pregabalin had
a combined NNT of 4.2 (95% CI 3.4–5.4) and NNH for
withdrawal of 11.7 (95% CI 8.3–19.9) [13].
Pregabalin has potential for abuse and dependence [14].
In the United States, it has been designated as a Schedule
V controlled substance by the Drug Enforcement Admin-
istration (DEA), as it has psychological effects that are
similar to those of diazepam and alprazolam. A history of
drug abuse should be evaluated before starting treatment
and signs of pregabalin abuse (including dose escalation,
tolerance and drug-seeking behaviour) should be mon-
itored during its administration.
Antidepressants
Antidepressants have analgesic effects that are indepen-
dent of their antidepressant activities [15]. Tricyclic
antidepressants (TCAs) relieve various peripheral neuro-
pathic pain conditions except HIV-related neuropathies
(Table 4). Until recently, the efficacy of these drugs hasight © European Society of Anaesthesiology. Una
Table 4 Antidepressants for all types of chronic neuropathic pain
Neuropathic pain conditions NNT for moderate pain relief or b
Diabetic neuropathy 1.3 (95% CI 1.2–1.5) RR 12.4 (9
PHN 2.7 (95% CI 2–4.1) RR 2.2 (95%
CI, confidence interval; NNT, number needed to treat; PHN, postherpetic neuralgia; Rbeen ascribed to inhibition of serotonin and noradrena-
line reuptake. TCAs overall (Table 5 for individual
agents) had a NNT of 3.6 (95% CI 3–4.5) [relative risk
(RR) 2.1 (95%CI 1.8–2.5)] for the achievement of at least
moderate pain relief in neuropathic pain, a NNH for
adverse effects of 6 (95% CI 4.2–10.7), and a NNH for
withdrawal of 28 (95% CI 17–68) [16]. The use of TCAs
is usually limited by significant anticholinergic, antihis-
taminergic, or a-adrenergic side effects particularly in the
elderly. There are some new data on better-tolerated
antidepressants, such as venlafaxine and duloxetine, in
the treatment of neuropathic pain.
Venlafaxine, which also exerts the same dual inhibitory
action on serotonin and noradrenaline reuptake [17], had
aNNTof 3.1 (95%CI 2.2–5.1) [RR 2.2 (95%CI 1.5–3.1)]
for the achievement of moderate pain relief or better in
neuropathic pain, a NNH for adverse effects of 9 (95% CI
3.5–13) and a NNH for withdrawal of 16 (95% CI 8–436)
[16]. The efficacy of duloxetine has been established in
three clinical trials involving 1139 patients with painful
DPN [18]. Duloxetine, a balanced serotonin–noradrena-
line reuptake inhibitor (SNRI), is the first and currently
the only antidepressant to be licensed for the treatment
of painful DPN. At doses of 60mg once or twice daily, it
had a rapid and sustained analgesic effect [19]. There
were significantly greater improvements in functional
outcomes and QoL parameters in duloxetine-treated
patients compared with patients who received placebo
[20]. None of these clinical trials included data that could
be used in NNT calculations.
Topical agents
There is a growing body of evidence on the efficacy of
topical agents in a variety of neuropathic pain conditions.
Topical analgesics have favourable safety profiles anduthorized reproduction of this article is prohibited.
etter (compared with placebo) Pooled sample size
5% CI 5.2–29.2) 177 patients (five studies)
CI 1.6–3.1) 219 patients (four studies)
R, relative risk. Adapted from [8].
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Table 5 Tricyclic antidepressants for chronic neuropathic pain
TCAs NNT for moderate pain relief or better (compared with placebo) Pooled sample size
Amitriptyline (up to 150 mg daily) 3.1 (95% CI 2.5–4.2) 588 patients (10 studies)
Desipramine 2.6 (95% CI 1.9–4.5) 100 patients (two studies)
Imipramine 2.2 (95% CI 1.7–3.22) 114 patients (three studies)
CI, confidence interval; NNT, number needed to treat; TCAs, tricyclic antidepressants. Adapted from [8].minimal risk of drug–drug interactions because of their
localized activities and low systemic absorption.
Transdermal lidocaine plaster is licensed for the treat-
ment of PHN. The presumed mechanism of action is
mainly via peripheral sodium-channel blockade [21]. On
the basis of data from 58 patients with peripheral neuro-
pathic pain syndromes, lidocaine plaster 5% had a NNT
of 3.6 (95% CI 2.2–11.7) for a 30% reduction in pain and
4.4 (95% CI 2.5–17.5) for a 50% ongoing pain reduction
[22]. It was generally well tolerated but application site
reactions were common. Dosage titration is not necessary
and up to three plasters (420 cm2) may be applied once
daily for a maximum of 12 hday1. For the treatment of
PHN, lidocaine plaster is more expensive than other
adjuvant analgesics and should be reserved as an option
for treatment-resistant patients only.
Capsaicin and several related compounds called capsai-
cinoids are produced as a secondary metabolite by chili
peppers, probably as deterrents against herbivores. Pure
capsaicin is a hydrophobic, colourless, odourless, crystal-
line to waxy compound and is a chemical irritant. It
selectively binds to transient receptor potential vanilloid
type 1 (TRPV1) receptors on the membranes of pain and
heat-sensing neurons. TRPV1 is a heat-activated channel
that is nonselective for cations and modestly permeable
to calcium, with permeability ratios of calcium to sodium
between four (heat-activated current) and 10 (capsaicin-
activated current) [23]. When capsaicin binds to TRPV1,
it causes the channel to lower its opening threshold,
thereby opening it at temperatures less than the body’s
temperature, which is why capsaicin is linked to the
sensation of heat. Prolonged activation of these neurons
by capsaicin depletes presynaptic substance P, one of the
body’s neurotransmitters for pain and heat. Neurons that
do not contain TRPV1 are unaffected [24]. Topical
capsaicin 0.075% was evaluated in a meta-analysis with
data from 665 patients (six clinical studies) for neuro-
pathic conditions [25]. The NNTs for a 50% reduction in
pain from 4 and 8-week treatment compared with placebo
were 6.4 (95% CI 3.8–21) and 5.7 (95% CI 4–10),
respectively. Treatment had to be applied three or four
times daily. The NNH for adverse event-related with-
drawals was 7.5 (95% CI 5.5–12). Common local adverse
effects were redness, stinging, and burning sensation.
Cannabinoids
Evidence from animal studies and preclinical data
suggest that cannabinoids have analgesic properties.right © European Society of Anaesthesiology. UnSativex (GW Pharmaceuticals, Salisbury, Wiltshire,
UK), a cannabis plant-based prescription pharmaceutical
product administered as an oromucosal spray delivering a
fixed dose of 2.7mg tetrahydrocannabinol (THC) and
2.5mg cannabidiol (CBD), was approved in Canada for
multiple sclerosis-related central neuropathic pain in
2005 and is available in the UK as an unlicensed medi-
cine. It is also available in Catalonia, Spain, for 600
patients with multiple sclerosis and a number of other
conditions under a compassionate access programme.
Cannabinoids target two specific receptors: CB1 and
CB2 [26]. On the basis of clinical data from 298 patients
(seven studies, mostly crossover design) with multiple
sclerosis-related neuropathic pain, cannabinoid-based
treatments produced endpoint-baseline score reductions
of 1.6 0.4 points on the 11-point pain rating scale
(P< 0.001) [27]. A reduction of approximately 2 points
from baseline on an 11-point pain rating scale or a 30%
reduction on pain severity from baseline represents clini-
cally meaningful improvement [28]; however, crossover
trials tend to overestimate efficacy because intention to
treat analysis cannot be used. Dizziness is commonly
associated with cannabinoid-based treatments.
Ziconotide
Ziconotide is a synthetic equivalent of a naturally occur-
ring conopeptide (v-conotoxin M-VII-A), an N-type
calcium-channel blocker found in the piscivorous marine
snail, Conus magus [29]. Ziconotide, as an intrathecal
infusion, is approved by the Food and Drug Adminis-
tration (FDA) of the United States for themanagement of
severe chronic pain in patients who are intolerant of or
refractory to other treatments. The emerging evidence of
using ziconotide for severe refractory neuropathic pain is
promising but limited to very little clinical data (mainly
from case reports). Common adverse effects are dizziness,
nausea, confusion and nystagmus. Ziconotide is contra-
indicated for patients with certain preexisting mental
disorders (e.g. psychosis) due to evidence that they are
more susceptible to certain severe side effects.
Future developments
There are at least 50 new agents undergoing clinical
development for neuropathic pain and eight drugs are
in phase III clinical trials at present, including glutamate
antagonists, cytokine inhibitors, vanilloid-receptor ago-
nists, catecholamine modulators, ion-channel blockers,
anticonvulsants, opioids, cannabinoids, cyclo-oxygenase
(COX) inhibitors, acteylcholine modulators, adenosine
receptor agonists and several miscellaneous drugs [30].authorized reproduction of this article is prohibited.
Copyr
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topiramate, lamotrigine, sodium valproate, clonazepam,
mexiletine, and amantadine. Preclinical studies suggest
that gene therapy, stem cell therapy and viral vectors
for delivery of biologic antinociceptive molecules are
emerging options.
Conclusion
There is good evidence supporting the use of adjuvant
analgesics in neuropathic pain, especially for those com-
mon neuropathic pain conditions such as trigeminal
neuralgia, painful DPN and PHN; however, the data
on adjuvant analgesics in central neuropathic pain are
limited. The selection of an adjuvant analgesic for neuro-
pathic pain should be based on proven efficacy, toler-
ability, safety, toxicity, drug interactions, ease of use and
cost-effectiveness. The evidence to support switching of
drugs within the same class or between different classes is
weak. Combination therapy, in most cases, is also not
evidence based. Even the most appropriate treatment
strategy may only be able, at best, to reduce neuropathic
pain to a more tolerable level.
At the moment, most clinical trials of neuropathic pain
conditions have focused mainly on disease-based but
rarely symptom-based treatment, based on the premise
that neuropathic pain medications should be selected by
the aetiology of the patient’s disease and not by the
patient’s symptoms. Future studies should be focused
on mechanisms responsible for the initiation or mainten-
ance of neuropathic pain.
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